Table of Content

1 Influenzavirus B Infection Drug Market Overview
1.1 Influenzavirus B Infection Drug Product Overview
1.2 Influenzavirus B Infection Drug Market Segment by Type
1.2.1 APP-309
1.2.2 CF-403
1.2.3 GC-3106A
1.2.4 KIN-1400
1.2.5 Others
1.3 Global Influenzavirus B Infection Drug Market Size by Type
1.3.1 Global Influenzavirus B Infection Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Influenzavirus B Infection Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Influenzavirus B Infection Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Influenzavirus B Infection Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Influenzavirus B Infection Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Influenzavirus B Infection Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Influenzavirus B Infection Drug Sales Breakdown by Type (2018-2024)
2 Global Influenzavirus B Infection Drug Market Competition by Company
2.1 Global Top Players by Influenzavirus B Infection Drug Sales (2018-2024)
2.2 Global Top Players by Influenzavirus B Infection Drug Revenue (2018-2024)
2.3 Global Top Players by Influenzavirus B Infection Drug Price (2018-2024)
2.4 Global Top Manufacturers Influenzavirus B Infection Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Influenzavirus B Infection Drug Market Competitive Situation and Trends
2.5.1 Influenzavirus B Infection Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Influenzavirus B Infection Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Influenzavirus B Infection Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Influenzavirus B Infection Drug Market
2.8 Key Manufacturers Influenzavirus B Infection Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Influenzavirus B Infection Drug Status and Outlook by Region
3.1 Global Influenzavirus B Infection Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Influenzavirus B Infection Drug Historic Market Size by Region
3.2.1 Global Influenzavirus B Infection Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Influenzavirus B Infection Drug Sales in Value by Region (2018-2024)
3.2.3 Global Influenzavirus B Infection Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Region
3.3.1 Global Influenzavirus B Infection Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Influenzavirus B Infection Drug Sales in Value by Region (2024-2034)
3.3.3 Global Influenzavirus B Infection Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Influenzavirus B Infection Drug by Application
4.1 Influenzavirus B Infection Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Influenzavirus B Infection Drug Market Size by Application
4.2.1 Global Influenzavirus B Infection Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Influenzavirus B Infection Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Influenzavirus B Infection Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Influenzavirus B Infection Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Influenzavirus B Infection Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Influenzavirus B Infection Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Influenzavirus B Infection Drug Sales Breakdown by Application (2018-2024)
5 North America Influenzavirus B Infection Drug by Country
5.1 North America Influenzavirus B Infection Drug Historic Market Size by Country
5.1.1 North America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Influenzavirus B Infection Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Influenzavirus B Infection Drug Sales in Value by Country (2018-2024)
5.2 North America Influenzavirus B Infection Drug Forecasted Market Size by Country
5.2.1 North America Influenzavirus B Infection Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Influenzavirus B Infection Drug Sales in Value by Country (2024-2034)
6 Europe Influenzavirus B Infection Drug by Country
6.1 Europe Influenzavirus B Infection Drug Historic Market Size by Country
6.1.1 Europe Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Influenzavirus B Infection Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Influenzavirus B Infection Drug Sales in Value by Country (2018-2024)
6.2 Europe Influenzavirus B Infection Drug Forecasted Market Size by Country
6.2.1 Europe Influenzavirus B Infection Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Influenzavirus B Infection Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Influenzavirus B Infection Drug by Region
7.1 Asia-Pacific Influenzavirus B Infection Drug Historic Market Size by Region
7.1.1 Asia-Pacific Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Influenzavirus B Infection Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Influenzavirus B Infection Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Influenzavirus B Infection Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Influenzavirus B Infection Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Influenzavirus B Infection Drug Sales in Value by Region (2024-2034)
8 Latin America Influenzavirus B Infection Drug by Country
8.1 Latin America Influenzavirus B Infection Drug Historic Market Size by Country
8.1.1 Latin America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Influenzavirus B Infection Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Influenzavirus B Infection Drug Sales in Value by Country (2018-2024)
8.2 Latin America Influenzavirus B Infection Drug Forecasted Market Size by Country
8.2.1 Latin America Influenzavirus B Infection Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Influenzavirus B Infection Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Influenzavirus B Infection Drug by Country
9.1 Middle East and Africa Influenzavirus B Infection Drug Historic Market Size by Country
9.1.1 Middle East and Africa Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Influenzavirus B Infection Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Influenzavirus B Infection Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Influenzavirus B Infection Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Influenzavirus B Infection Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Influenzavirus B Infection Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 AbbVie Inc
10.1.1 AbbVie Inc Company Information
10.1.2 AbbVie Inc Introduction and Business Overview
10.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
10.1.5 AbbVie Inc Recent Development
10.2 Adimmune Corp
10.2.1 Adimmune Corp Company Information
10.2.2 Adimmune Corp Introduction and Business Overview
10.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered
10.2.5 Adimmune Corp Recent Development
10.3 Altravax Inc
10.3.1 Altravax Inc Company Information
10.3.2 Altravax Inc Introduction and Business Overview
10.3.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered
10.3.5 Altravax Inc Recent Development
10.4 Amarillo Biosciences Inc
10.4.1 Amarillo Biosciences Inc Company Information
10.4.2 Amarillo Biosciences Inc Introduction and Business Overview
10.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered
10.4.5 Amarillo Biosciences Inc Recent Development
10.5 Aphios Corp
10.5.1 Aphios Corp Company Information
10.5.2 Aphios Corp Introduction and Business Overview
10.5.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered
10.5.5 Aphios Corp Recent Development
10.6 BioCryst Pharmaceuticals Inc
10.6.1 BioCryst Pharmaceuticals Inc Company Information
10.6.2 BioCryst Pharmaceuticals Inc Introduction and Business Overview
10.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
10.6.5 BioCryst Pharmaceuticals Inc Recent Development
10.7 Cadila Healthcare Ltd
10.7.1 Cadila Healthcare Ltd Company Information
10.7.2 Cadila Healthcare Ltd Introduction and Business Overview
10.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered
10.7.5 Cadila Healthcare Ltd Recent Development
10.8 ContraFect Corp
10.8.1 ContraFect Corp Company Information
10.8.2 ContraFect Corp Introduction and Business Overview
10.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered
10.8.5 ContraFect Corp Recent Development
10.9 Daiichi Sankyo Company Ltd
10.9.1 Daiichi Sankyo Company Ltd Company Information
10.9.2 Daiichi Sankyo Company Ltd Introduction and Business Overview
10.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered
10.9.5 Daiichi Sankyo Company Ltd Recent Development
10.10 Fujifilm Holdings Corporation
10.10.1 Fujifilm Holdings Corporation Company Information
10.10.2 Fujifilm Holdings Corporation Introduction and Business Overview
10.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered
10.10.5 Fujifilm Holdings Corporation Recent Development
10.11 GlaxoSmithKline Plc
10.11.1 GlaxoSmithKline Plc Company Information
10.11.2 GlaxoSmithKline Plc Introduction and Business Overview
10.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Products Offered
10.11.5 GlaxoSmithKline Plc Recent Development
10.12 Green Cross Corp
10.12.1 Green Cross Corp Company Information
10.12.2 Green Cross Corp Introduction and Business Overview
10.12.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Green Cross Corp Influenzavirus B Infection Drug Products Offered
10.12.5 Green Cross Corp Recent Development
10.13 Inovio Pharmaceuticals Inc
10.13.1 Inovio Pharmaceuticals Inc Company Information
10.13.2 Inovio Pharmaceuticals Inc Introduction and Business Overview
10.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
10.13.5 Inovio Pharmaceuticals Inc Recent Development
10.14 Kineta Inc
10.14.1 Kineta Inc Company Information
10.14.2 Kineta Inc Introduction and Business Overview
10.14.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Kineta Inc Influenzavirus B Infection Drug Products Offered
10.14.5 Kineta Inc Recent Development
10.15 Medicago Inc
10.15.1 Medicago Inc Company Information
10.15.2 Medicago Inc Introduction and Business Overview
10.15.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Medicago Inc Influenzavirus B Infection Drug Products Offered
10.15.5 Medicago Inc Recent Development
10.16 MedImmune LLC
10.16.1 MedImmune LLC Company Information
10.16.2 MedImmune LLC Introduction and Business Overview
10.16.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.16.4 MedImmune LLC Influenzavirus B Infection Drug Products Offered
10.16.5 MedImmune LLC Recent Development
10.17 Mucosis BV
10.17.1 Mucosis BV Company Information
10.17.2 Mucosis BV Introduction and Business Overview
10.17.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Mucosis BV Influenzavirus B Infection Drug Products Offered
10.17.5 Mucosis BV Recent Development
10.18 Novavax Inc
10.18.1 Novavax Inc Company Information
10.18.2 Novavax Inc Introduction and Business Overview
10.18.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Novavax Inc Influenzavirus B Infection Drug Products Offered
10.18.5 Novavax Inc Recent Development
10.19 Park Active Molecules
10.19.1 Park Active Molecules Company Information
10.19.2 Park Active Molecules Introduction and Business Overview
10.19.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.19.4 Park Active Molecules Influenzavirus B Infection Drug Products Offered
10.19.5 Park Active Molecules Recent Development
10.20 Romark Laboratories LC
10.20.1 Romark Laboratories LC Company Information
10.20.2 Romark Laboratories LC Introduction and Business Overview
10.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.20.4 Romark Laboratories LC Influenzavirus B Infection Drug Products Offered
10.20.5 Romark Laboratories LC Recent Development
10.21 Sanofi
10.21.1 Sanofi Company Information
10.21.2 Sanofi Introduction and Business Overview
10.21.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.21.4 Sanofi Influenzavirus B Infection Drug Products Offered
10.21.5 Sanofi Recent Development
10.22 Sanofi Pasteur SA
10.22.1 Sanofi Pasteur SA Company Information
10.22.2 Sanofi Pasteur SA Introduction and Business Overview
10.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.22.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Products Offered
10.22.5 Sanofi Pasteur SA Recent Development
10.23 Shionogi & Co Ltd
10.23.1 Shionogi & Co Ltd Company Information
10.23.2 Shionogi & Co Ltd Introduction and Business Overview
10.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.23.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Products Offered
10.23.5 Shionogi & Co Ltd Recent Development
10.24 SK Chemicals Co Ltd
10.24.1 SK Chemicals Co Ltd Company Information
10.24.2 SK Chemicals Co Ltd Introduction and Business Overview
10.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.24.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Products Offered
10.24.5 SK Chemicals Co Ltd Recent Development
10.25 TSRL Inc
10.25.1 TSRL Inc Company Information
10.25.2 TSRL Inc Introduction and Business Overview
10.25.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.25.4 TSRL Inc Influenzavirus B Infection Drug Products Offered
10.25.5 TSRL Inc Recent Development
10.26 Vaxart Inc
10.26.1 Vaxart Inc Company Information
10.26.2 Vaxart Inc Introduction and Business Overview
10.26.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.26.4 Vaxart Inc Influenzavirus B Infection Drug Products Offered
10.26.5 Vaxart Inc Recent Development
10.27 Vectura Group Plc
10.27.1 Vectura Group Plc Company Information
10.27.2 Vectura Group Plc Introduction and Business Overview
10.27.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2018-2024)
10.27.4 Vectura Group Plc Influenzavirus B Infection Drug Products Offered
10.27.5 Vectura Group Plc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Influenzavirus B Infection Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Influenzavirus B Infection Drug Industrial Chain Analysis
11.4 Influenzavirus B Infection Drug Market Dynamics
11.4.1 Influenzavirus B Infection Drug Industry Trends
11.4.2 Influenzavirus B Infection Drug Market Drivers
11.4.3 Influenzavirus B Infection Drug Market Challenges
11.4.4 Influenzavirus B Infection Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Influenzavirus B Infection Drug Distributors
12.3 Influenzavirus B Infection Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of APP-309
Table 2. Major Company of CF-403
Table 3. Major Company of GC-3106A
Table 4. Major Company of KIN-1400
Table 5. Major Company of Others
Table 6. Global Influenzavirus B Infection Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Influenzavirus B Infection Drug Sales by Type (2018-2024) & (K Pcs)
Table 8. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Type (2018-2024)
Table 9. Global Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US& Million)
Table 10. Global Influenzavirus B Infection Drug Market Share in Value by Type (2018-2024)
Table 11. Global Influenzavirus B Infection Drug Price by Type (2018-2024) & (USD/Pcs)
Table 12. Global Influenzavirus B Infection Drug Sales by Type (2024-2034) & (K Pcs)
Table 13. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Type (2024-2034)
Table 14. Global Influenzavirus B Infection Drug Sales by Type (2024-2034) & (US$ Million)
Table 15. Global Influenzavirus B Infection Drug Sales Market Share in Value by Type (2024-2034)
Table 16. Global Influenzavirus B Infection Drug Price by Type (2024-2034) & (USD/Pcs)
Table 17. North America Influenzavirus B Infection Drug Sales by Type (2018-2024) & (K Pcs)
Table 18. North America Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US$ Million)
Table 19. Europe Influenzavirus B Infection Drug Sales (K Pcs) by Type (2018-2024)
Table 20. Europe Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US$ Million)
Table 21. Asia-Pacific Influenzavirus B Infection Drug Sales (K Pcs) by Type (2018-2024)
Table 22. Asia-Pacific Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US$ Million)
Table 23. Latin America Influenzavirus B Infection Drug Sales (K Pcs) by Type (2018-2024)
Table 24. Latin America Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US$ Million)
Table 25. Middle East and Africa Influenzavirus B Infection Drug Sales (K Pcs) by Type (2018-2024)
Table 26. Middle East and Africa Influenzavirus B Infection Drug Sales by Type (2018-2024) & (US$ Million)
Table 27. Global Influenzavirus B Infection Drug Sales by Company (2018-2024) & (K Pcs)
Table 28. Global Influenzavirus B Infection Drug Sales Share by Company (2018-2024)
Table 29. Global Influenzavirus B Infection Drug Revenue by Company (2018-2024) & (US$ Million)
Table 30. Global Influenzavirus B Infection Drug Revenue Share by Company (2018-2024)
Table 31. Global Market Influenzavirus B Infection Drug Price by Company (2018-2024) & (USD/Pcs)
Table 32. Global Influenzavirus B Infection Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 33. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 34. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Influenzavirus B Infection Drug as of 2022)
Table 35. Date of Key Manufacturers Enter into Influenzavirus B Infection Drug Market
Table 36. Key Manufacturers Influenzavirus B Infection Drug Product Type
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Influenzavirus B Infection Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 39. Global Influenzavirus B Infection Drug Sales by Region (2018-2024) & (K Pcs)
Table 40. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2018-2024)
Table 41. Global Influenzavirus B Infection Drug Sales by Region (2018-2024) & (US$ Million)
Table 42. Global Influenzavirus B Infection Drug Sales Market Share in Value by Region (2018-2024)
Table 43. Global Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 44. Global Influenzavirus B Infection Drug Sales by Region (2024-2034) & (K Pcs)
Table 45. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2024-2034)
Table 46. Global Influenzavirus B Infection Drug Sales by Region (2024-2034) & (US$ Million)
Table 47. Global Influenzavirus B Infection Drug Sales Market Share in Value by Region (2024-2034)
Table 48. Global Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 49. Global Influenzavirus B Infection Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 50. Global Influenzavirus B Infection Drug Sales by Application (2018-2024) & (K Pcs)
Table 51. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Application (2018-2024)
Table 52. Global Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 53. Global Influenzavirus B Infection Drug Sales Market Share in Value by Application (2018-2024)
Table 54. Global Influenzavirus B Infection Drug Price by Application (2018-2024) & (USD/Pcs)
Table 55. Global Influenzavirus B Infection Drug Sales by Application (2024-2034) & (K Pcs)
Table 56. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Application (2024-2034)
Table 57. Global Influenzavirus B Infection Drug Sales by Application (2024-2034) & (US$ Million)
Table 58. Global Influenzavirus B Infection Drug Sales Market Share in Value by Application (2024-2034)
Table 59. Global Influenzavirus B Infection Drug Price by Application (2024-2034) & (USD/Pcs)
Table 60. North America Influenzavirus B Infection Drug Sales by Application (2018-2024) (K Pcs)
Table 61. North America Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 62. Europe Influenzavirus B Infection Drug Sales by Application (2018-2024) (K Pcs)
Table 63. Europe Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 64. Asia-Pacific Influenzavirus B Infection Drug Sales by Application (2018-2024) (K Pcs)
Table 65. Asia-Pacific Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 66. Latin America Influenzavirus B Infection Drug Sales by Application (2018-2024) (K Pcs)
Table 67. Latin America Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 68. Middle East and Africa Influenzavirus B Infection Drug Sales by Application (2018-2024) (K Pcs)
Table 69. Middle East and Africa Influenzavirus B Infection Drug Sales by Application (2018-2024) & (US$ Million)
Table 70. North America Influenzavirus B Infection Drug Sales by Country (2018-2024) & (K Pcs)
Table 71. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2018-2024)
Table 72. North America Influenzavirus B Infection Drug Sales by Country (2018-2024) & (US$ Million)
Table 73. North America Influenzavirus B Infection Drug Sales Market Share in Value by Country (2018-2024)
Table 74. North America Influenzavirus B Infection Drug Sales by Country (2024-2034) & (K Pcs)
Table 75. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2024-2034)
Table 76. North America Influenzavirus B Infection Drug Sales by Country (2024-2034) & (US$ Million)
Table 77. North America Influenzavirus B Infection Drug Sales Market Share in Value by Country (2024-2034)
Table 78. Europe Influenzavirus B Infection Drug Sales by Country (2018-2024) & (K Pcs)
Table 79. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2018-2024)
Table 80. Europe Influenzavirus B Infection Drug Sales by Country (2018-2024) & (US$ Million)
Table 81. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Country (2018-2024)
Table 82. Europe Influenzavirus B Infection Drug Sales by Country (2024-2034) & (K Pcs)
Table 83. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2024-2034)
Table 84. Europe Influenzavirus B Infection Drug Sales by Country (2024-2034) & (US$ Million)
Table 85. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Country (2024-2034)
Table 86. Asia-Pacific Influenzavirus B Infection Drug Sales by Region (2018-2024) & (K Pcs)
Table 87. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2018-2024)
Table 88. Asia-Pacific Influenzavirus B Infection Drug Sales by Region (2018-2024) & (US$ Million)
Table 89. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Region (2018-2024)
Table 90. Asia-Pacific Influenzavirus B Infection Drug Sales by Region (2024-2034) & (K Pcs)
Table 91. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2024-2034)
Table 92. Asia-Pacific Influenzavirus B Infection Drug Sales by Region (2024-2034) & (US$ Million)
Table 93. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Region (2024-2034)
Table 94. Latin America Influenzavirus B Infection Drug Sales by Country (2018-2024) & (K Pcs)
Table 95. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2018-2024)
Table 96. Latin America Influenzavirus B Infection Drug Sales by Country (2018-2024) & (US$ Million)
Table 97. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Country (2018-2024)
Table 98. Latin America Influenzavirus B Infection Drug Sales by Country (2024-2034) & (K Pcs)
Table 99. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2024-2034)
Table 100. Latin America Influenzavirus B Infection Drug Sales by Country (2024-2034) & (US$ Million)
Table 101. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Country (2024-2034)
Table 102. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2018-2024) & (K Pcs)
Table 103. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2018-2024)
Table 104. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2018-2024) & (US$ Million)
Table 105. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Country (2018-2024)
Table 106. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2024-2034) & (K Pcs)
Table 107. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Volume by Country (2024-2034)
Table 108. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2024-2034) & (US$ Million)
Table 109. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Country (2024-2034)
Table 110. AbbVie Inc Company Information
Table 111. AbbVie Inc Introduction and Business Overview
Table 112. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. AbbVie Inc Influenzavirus B Infection Drug Product
Table 114. AbbVie Inc Recent Development
Table 115. Adimmune Corp Company Information
Table 116. Adimmune Corp Introduction and Business Overview
Table 117. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Adimmune Corp Influenzavirus B Infection Drug Product
Table 119. Adimmune Corp Recent Development
Table 120. Altravax Inc Company Information
Table 121. Altravax Inc Introduction and Business Overview
Table 122. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Altravax Inc Influenzavirus B Infection Drug Product
Table 124. Altravax Inc Recent Development
Table 125. Amarillo Biosciences Inc Company Information
Table 126. Amarillo Biosciences Inc Introduction and Business Overview
Table 127. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product
Table 129. Amarillo Biosciences Inc Recent Development
Table 130. Aphios Corp Company Information
Table 131. Aphios Corp Introduction and Business Overview
Table 132. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Aphios Corp Influenzavirus B Infection Drug Product
Table 134. Aphios Corp Recent Development
Table 135. BioCryst Pharmaceuticals Inc Company Information
Table 136. BioCryst Pharmaceuticals Inc Introduction and Business Overview
Table 137. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product
Table 139. BioCryst Pharmaceuticals Inc Recent Development
Table 140. Cadila Healthcare Ltd Company Information
Table 141. Cadila Healthcare Ltd Introduction and Business Overview
Table 142. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 143. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product
Table 144. Cadila Healthcare Ltd Recent Development
Table 145. ContraFect Corp Company Information
Table 146. ContraFect Corp Introduction and Business Overview
Table 147. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 148. ContraFect Corp Influenzavirus B Infection Drug Product
Table 149. ContraFect Corp Recent Development
Table 150. Daiichi Sankyo Company Ltd Company Information
Table 151. Daiichi Sankyo Company Ltd Introduction and Business Overview
Table 152. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 153. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product
Table 154. Daiichi Sankyo Company Ltd Recent Development
Table 155. Fujifilm Holdings Corporation Company Information
Table 156. Fujifilm Holdings Corporation Introduction and Business Overview
Table 157. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 158. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product
Table 159. Fujifilm Holdings Corporation Recent Development
Table 160. GlaxoSmithKline Plc Company Information
Table 161. GlaxoSmithKline Plc Introduction and Business Overview
Table 162. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 163. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product
Table 164. GlaxoSmithKline Plc Recent Development
Table 165. Green Cross Corp Company Information
Table 166. Green Cross Corp Introduction and Business Overview
Table 167. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 168. Green Cross Corp Influenzavirus B Infection Drug Product
Table 169. Green Cross Corp Recent Development
Table 170. Inovio Pharmaceuticals Inc Company Information
Table 171. Inovio Pharmaceuticals Inc Introduction and Business Overview
Table 172. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 173. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product
Table 174. Inovio Pharmaceuticals Inc Recent Development
Table 175. Kineta Inc Company Information
Table 176. Kineta Inc Introduction and Business Overview
Table 177. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 178. Kineta Inc Influenzavirus B Infection Drug Product
Table 179. Kineta Inc Recent Development
Table 180. Medicago Inc Company Information
Table 181. Medicago Inc Introduction and Business Overview
Table 182. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 183. Medicago Inc Influenzavirus B Infection Drug Product
Table 184. Medicago Inc Recent Development
Table 185. MedImmune LLC Company Information
Table 186. MedImmune LLC Introduction and Business Overview
Table 187. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 188. MedImmune LLC Influenzavirus B Infection Drug Product
Table 189. MedImmune LLC Recent Development
Table 190. Mucosis BV Company Information
Table 191. Mucosis BV Introduction and Business Overview
Table 192. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 193. Mucosis BV Influenzavirus B Infection Drug Product
Table 194. Mucosis BV Recent Development
Table 195. Novavax Inc Company Information
Table 196. Novavax Inc Introduction and Business Overview
Table 197. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 198. Novavax Inc Influenzavirus B Infection Drug Product
Table 199. Novavax Inc Recent Development
Table 200. Park Active Molecules Company Information
Table 201. Park Active Molecules Introduction and Business Overview
Table 202. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 203. Park Active Molecules Influenzavirus B Infection Drug Product
Table 204. Park Active Molecules Recent Development
Table 205. Romark Laboratories LC Company Information
Table 206. Romark Laboratories LC Introduction and Business Overview
Table 207. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 208. Romark Laboratories LC Influenzavirus B Infection Drug Product
Table 209. Romark Laboratories LC Recent Development
Table 210. Sanofi Company Information
Table 211. Sanofi Introduction and Business Overview
Table 212. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 213. Sanofi Influenzavirus B Infection Drug Product
Table 214. Sanofi Recent Development
Table 215. Sanofi Pasteur SA Company Information
Table 216. Sanofi Pasteur SA Introduction and Business Overview
Table 217. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 218. Sanofi Pasteur SA Influenzavirus B Infection Drug Product
Table 219. Sanofi Pasteur SA Recent Development
Table 220. Shionogi & Co Ltd Company Information
Table 221. Shionogi & Co Ltd Introduction and Business Overview
Table 222. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 223. Shionogi & Co Ltd Influenzavirus B Infection Drug Product
Table 224. Shionogi & Co Ltd Recent Development
Table 225. SK Chemicals Co Ltd Company Information
Table 226. SK Chemicals Co Ltd Introduction and Business Overview
Table 227. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 228. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product
Table 229. SK Chemicals Co Ltd Recent Development
Table 230. TSRL Inc Introduction and Business Overview
Table 231. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 232. TSRL Inc Influenzavirus B Infection Drug Product
Table 233. TSRL Inc Recent Development
Table 234. TSRL Inc Company Information
Table 235. Vaxart Inc Company Information
Table 236. Vaxart Inc Introduction and Business Overview
Table 237. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 238. Vaxart Inc Influenzavirus B Infection Drug Product
Table 239. Vaxart Inc Recent Development
Table 240. Vectura Group Plc Company Information
Table 241. Vectura Group Plc Introduction and Business Overview
Table 242. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 243. Vectura Group Plc Influenzavirus B Infection Drug Product
Table 244. Vectura Group Plc Recent Development
Table 245. Key Raw Materials Lists
Table 246. Raw Materials Key Suppliers Lists
Table 247. Influenzavirus B Infection Drug Market Trends
Table 248. Influenzavirus B Infection Drug Market Drivers
Table 249. Influenzavirus B Infection Drug Market Challenges
Table 250. Influenzavirus B Infection Drug Market Restraints
Table 251. Influenzavirus B Infection Drug Distributors List
Table 252. Influenzavirus B Infection Drug Downstream Customers
Table 253. Research Programs/Design for This Report
Table 254. Key Data Information from Secondary Sources
Table 255. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenzavirus B Infection Drug Product Picture
Figure 2. Global Influenzavirus B Infection Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Influenzavirus B Infection Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Influenzavirus B Infection Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of APP-309
Figure 6. Global APP-309 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of CF-403
Figure 8. Global CF-403 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of GC-3106A
Figure 10. Global GC-3106A Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of KIN-1400
Figure 12. Global KIN-1400 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Others
Figure 14. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Global Influenzavirus B Infection Drug Sales by Type (2018-2034) & (US$ Million)
Figure 16. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2022 & 2034
Figure 17. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2022
Figure 18. North America Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2022
Figure 19. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2022
Figure 20. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2022
Figure 21. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2022
Figure 22. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2022
Figure 23. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2022
Figure 24. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2022
Figure 25. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2022
Figure 26. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2022
Figure 27. The 5 and 10 Largest Manufacturers in the World: Market Share by Influenzavirus B Infection Drug Sales in 2022
Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by Influenzavirus B Infection Drug Revenue in 2022
Figure 29. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Product Picture of Clinic
Figure 31. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 32. Product Picture of Hospital
Figure 33. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Others
Figure 35. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Global Influenzavirus B Infection Drug Sales by Application (2018-2034) & (US$ Million)
Figure 37. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2022 & 2034
Figure 38. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2022
Figure 39. North America Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2022
Figure 40. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2022
Figure 41. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2022
Figure 42. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2022
Figure 43. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2022
Figure 44. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2022
Figure 45. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2022
Figure 46. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2022
Figure 47. Key Raw Materials Price
Figure 48. Influenzavirus B Infection Drug Manufacturing Cost Structure
Figure 49. Influenzavirus B Infection Drug Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed